← All drugs
Drug · FAERS side-effect profile with label screen

Topiramate side effects: what 91,049 FDA adverse event reports show

Topiramate · 1,213 reaction terms · 435,044 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Cytochrome P450 3A4 Inducers, Cytochrome P450 2C19 Inhibitors

FDA label (mechanism-of-action class)

Who reports

91,049 reports · 69% serious · 6,839 with death outcome · 78% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Topiramate is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ( 1.1 ); adjunctive therapy for the treatment of partial-onset seizures, pri.

FDA label, Indications and Usage

What it is

Topiramate is a hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester.

PubChem CID 5284627 (ChEBI)

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 5Labeled (related wording) 6Likely indication confounding 3Reporting / coding artifact 1Lab value / disease marker 1Not in label — unassessed 24
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,173 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Hepatic enzyme79297.7
212.5–417.0ROR 297.9 · calibrated p 3e-11 ✓
124.1 EB05 102.8 · IC025 +5.8
3/3 methods agree
Not in label — unassessedserious n=78 · ♀ 100% (drug 78%) · 100% clinicianno trial arm names this drug
Visual perseveration75231.6
167.6–320.0ROR 231.8 · calibrated p 3e-10 ✓
110.8 EB05 91.3 · IC025 +5.6
3/3 methods agree
Not in label — unassessed♀ 100% (drug 78%) · 100% clinicianno trial arm names this drug
Acute myopia62128.8
94.2–176.1ROR 128.9 · calibrated p 3e-8 ✓
80.0 EB05 64.6 · IC025 +5.2
3/3 methods agree
Labeled adverse reaction
exact term
serious n=60 · ♀ 100% (drug 78%) · 100% clinicianno trial arm names this drug
Hypocholesterolaemia96102.6
80.6–130.7ROR 102.7 · calibrated p 1e-7 ✓
69.6 EB05 58.7 · IC025 +5.4
3/3 methods agree
Not in label — unassessedserious n=95 · ♀ 100% (drug 78%) · 100% clinicianno trial arm names this drug
Neovascularisation6373.7
55.4–98.0ROR 73.8 · calibrated p 2e-6 ✓
54.7 EB05 44.3 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=63 · ♀ 100% (drug 78%) · 100% clinicianno trial arm names this drug
Angle closure glaucoma59768.7
62.7–75.3ROR 69.2 · calibrated p 2e-6 ✓
52.7 EB05 49.2 · IC025 +5.5
3/3 methods agree
Labeled adverse reaction
exact term
serious n=571no trial arm names this drug
Facet joint syndrome62255.5
50.9–60.6ROR 55.9 · calibrated p 7e-6 ✓
44.6 EB05 41.7 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=621 · ♀ 100% (drug 78%) · 91% clinicianno trial arm names this drug
Multiple-drug resistance60955.4
50.7–60.5ROR 55.7 · calibrated p 7e-6 ✓
44.5 EB05 41.6 · IC025 +5.3
3/3 methods agree
Reporting / coding artifactserious n=495 · 100% clinicianno trial arm names this drug
Anhidrosis7349.3
38.3–63.6ROR 49.4 · calibrated p 2e-5 ✓
40.2 EB05 33.0 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=64 · ♀ 0% (drug 78%)no trial arm names this drug
Acidosis hyperchloraemic9845.1
36.3–56.0ROR 45.2 · calibrated p 3e-5 ✓
37.4 EB05 31.6 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=97 · 100% clinicianno trial arm names this drug
Phonophobia6637.9
29.2–49.2ROR 37.9 · calibrated p 9e-5 ✓
32.3 EB05 26.2 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=63 · ♀ 0% (drug 78%) · 100% clinicianno trial arm names this drug
Infantile spasms10137.1
30.1–45.8ROR 37.2 · calibrated p 9e-5 ✓
31.8 EB05 26.9 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=101 · ♀ 0% (drug 78%)no trial arm names this drug
Hypohidrosis6936.6
28.4–47.2ROR 36.6 · calibrated p 1e-4 ✓
31.3 EB05 25.6 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=59 · 100% consumerno trial arm names this drug
Overlap syndrome9435.6
28.6–44.3ROR 35.6 · calibrated p 1e-4 ✓
30.7 EB05 25.8 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=94 · ♀ 100% (drug 78%) · 100% clinicianno trial arm names this drug
Onychomadesis56535.5
32.5–38.8ROR 35.7 · calibrated p 1e-4 ✓
30.7 EB05 28.7 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=562 · ♀ 100% (drug 78%) · 90% clinicianno trial arm names this drug
Blepharospasm82834.8
32.3–37.4ROR 35.1 · calibrated p 1e-4 ✓
30.2 EB05 28.5 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=798 · ♀ 100% (drug 78%)no trial arm names this drug
Myopia30333.1
29.3–37.3ROR 33.2 · calibrated p 2e-4 ✓
28.9 EB05 26.2 · IC025 +4.6
3/3 methods agree
Labeled adverse reaction
exact term
serious n=285no trial arm names this drug
Rheumatic fever52430.8
28.1–33.7ROR 30.9 · calibrated p 2e-4 ✓
27.1 EB05 25.2 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=524 · ♀ 100% (drug 78%) · 93% clinicianno trial arm names this drug
Cleft lip10630.7
25.1–37.6ROR 30.8 · calibrated p 3e-4 ✓
27.0 EB05 23.0 · IC025 +4.3
3/3 methods agree
Labeled adverse reaction
exact term
serious n=106 · ♀ 0% (drug 78%)no trial arm names this drug
Myoclonic epilepsy17530.4
26.0–35.6ROR 30.5 · calibrated p 3e-4 ✓
26.8 EB05 23.6 · IC025 +4.4
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=173no trial arm names this drug
Renal tubular acidosis25830.2
26.5–34.4ROR 30.3 · calibrated p 3e-4 ✓
26.6 EB05 24.0 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=257 · 100% clinicianno trial arm names this drug
Choroidal detachment6228.4
21.8–37.0ROR 28.4 · calibrated p 4e-4 ✓
25.1 EB05 20.3 · IC025 +4.0
3/3 methods agree
Labeled adverse reaction
exact term
serious n=62 · 100% clinicianno trial arm names this drug
Change in seizure presentation7127.4
21.4–35.0ROR 27.4 · calibrated p 5e-4 ✓
24.3 EB05 19.9 · IC025 +4.0
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=69 · ♀ 0% (drug 78%) · 100% clinicianno trial arm names this drug
Breast cancer stage iii65925.7
23.8–27.9ROR 25.9 · calibrated p 6e-4 ✓
23.2 EB05 21.7 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=659 · ♀ 100% (drug 78%) · 93% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody positive70724.9
23.1–26.9ROR 25.1 · calibrated p 7e-4 ✓
22.5 EB05 21.1 · IC025 +4.3
3/3 methods agree
Lab value / disease markerserious PRR 19.1 · ♀ 100% (drug 78%) · 92% clinicianno trial arm names this drug
Lupus vulgaris11524.1
19.9–29.2ROR 24.1 · calibrated p 9e-4 ✓
21.8 EB05 18.6 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=115 · ♀ 100% (drug 78%) · 100% clinicianno trial arm names this drug
Atonic seizures7423.1
18.2–29.3ROR 23.1 · calibrated p 0.001 ✓
20.9 EB05 17.2 · IC025 +3.8
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=69no trial arm names this drug
Hyperammonaemic encephalopathy15722.8
19.3–26.8ROR 22.8 · calibrated p 0.001 ✓
20.7 EB05 18.1 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=156 · ♀ 56% (drug 78%) · 100% clinicianno trial arm names this drug
Onychomycosis40022.7
20.5–25.1ROR 22.8 · calibrated p 0.001 ✓
20.6 EB05 19.0 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=396 · ♀ 100% (drug 78%) · 91% clinicianno trial arm names this drug
Finger deformity42921.9
19.8–24.2ROR 22.0 · calibrated p 0.001 ✓
20.0 EB05 18.5 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=426 · ♀ 100% (drug 78%)no trial arm names this drug
Duodenal ulcer perforation64621.8
20.1–23.6ROR 21.9 · calibrated p 0.001 ✓
19.9 EB05 18.6 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious PRR 16.8 · ♀ 100% (drug 78%) · 92% clinicianno trial arm names this drug
Dislocation of vertebra19421.5
18.6–25.0ROR 21.6 · calibrated p 0.001 ✓
19.7 EB05 17.5 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=194 · ♀ 100% (drug 78%) · 100% clinicianno trial arm names this drug
Heat stroke12120.2
16.8–24.3ROR 20.2 · calibrated p 0.002 ✓
18.6 EB05 15.9 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=120 · ♀ 0% (drug 78%) · 100% clinicianno trial arm names this drug
Self injurious behaviour25320.1
17.7–22.8ROR 20.1 · calibrated p 0.002 ✓
18.5 EB05 16.6 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=253no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Seizure6,7438.28.0–8.3signal
Suicidality3,8333.63.5–3.7signal
Depression4,2463.53.4–3.6signal
Extrapyramidal1,0052.22.1–2.3signal
Fall / fracture3,0201.81.8–1.9raised
Liver injury2,2231.71.6–1.8raised
Hyperglycaemia / diabetes2,2711.51.5–1.6raised
Rhabdomyolysis / myopathy5211.51.4–1.6raised
Pancreatitis4911.41.3–1.5raised
Venous thromboembolism1,2851.41.3–1.4raised
Anaphylaxis / angioedema7231.31.2–1.4raised
Severe cutaneous reaction3961.21.1–1.4raised
Serious infection4,0751.21.2–1.3raised
Tendon disorder1621.00.8–1.1no difference
Kidney injury1,8981.00.9–1.0no difference
Arrhythmia / qt7680.90.9–1.0lower than other drugs

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Topiramate only as a background or rescue medication (NCT00554216, NCT01922934); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)10,5331.8
1.8–1.9ROR 1.9 · calibrated p 0.900
1.8 EB05 1.8 · IC025 +0.8Reporting / coding artifactage-adj. PRR 2.1 · serious PRR 3.0no trial arm names this drug
Off label use (used outside approved label)7,6352.0
2.0–2.0ROR 2.1 · calibrated p 0.992
2.0 EB05 2.0 · IC025 +1.0Reporting / coding artifactage-adj. PRR 2.0 · serious PRR 2.4no trial arm names this drug
Headache6,6812.4
2.4–2.5ROR 2.5 · calibrated p 0.796
2.4 EB05 2.4 · IC025 +1.2
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.1 · serious PRR 2.8no trial arm names this drug
Nausea6,0181.7
1.7–1.8ROR 1.8 · calibrated p 0.819
1.7 EB05 1.7 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.9no trial arm names this drug
Fatigue (tiredness)5,5051.6
1.6–1.6ROR 1.6 · calibrated p 0.736
1.6 EB05 1.6 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.7no trial arm names this drug
Pain4,6591.7
1.7–1.8ROR 1.8 · calibrated p 0.804
1.7 EB05 1.7 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.9 · serious PRR 1.8no trial arm names this drug
Migraine4,58611.5
11.1–11.8ROR 12.0 · calibrated p 0.017 ✓
10.9 EB05 10.7 · IC025 +3.4
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 9.2 · serious PRR 12.6no trial arm names this drug
Dizziness4,2952.0
1.9–2.0ROR 2.0 · calibrated p 0.948
2.0 EB05 1.9 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 2.0 · serious PRR 2.1no trial arm names this drug
Seizure3,9037.9
7.7–8.2ROR 8.2 · calibrated p 0.061
7.7 EB05 7.5 · IC025 +2.9
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 5.4 · serious PRR 6.3no trial arm names this drug
Diarrhoea (diarrhea)3,8041.3
1.3–1.4ROR 1.4 · calibrated p 0.545
1.3 EB05 1.3 · IC025 +0.4Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.3no trial arm names this drug
Vomiting3,7261.8
1.7–1.9ROR 1.8 · calibrated p 0.853
1.8 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.8no trial arm names this drug
Depression3,6933.7
3.6–3.8ROR 3.8 · calibrated p 0.414
3.7 EB05 3.6 · IC025 +1.8
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 3.2 · serious PRR 3.6no trial arm names this drug
Product use in unapproved indication3,2833.1
3.0–3.2ROR 3.1 · calibrated p 0.581
3.0 EB05 3.0 · IC025 +1.5
3/3 methods agree
Reporting / coding artifactage-adj. PRR 3.0 · serious PRR 4.4no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Topiramate ↔ Acute angle-closure glaucoma.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Topiramate?

In FDA FAERS, the most frequently co-reported reaction terms for Topiramate are headache, nausea, fatigue, pain, migraine, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Topiramate have an FDA boxed warning?

No. The FDA label retrieved for Topiramate has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Topiramate causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.